Zealand Pharma A/S
F:22Z
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zealand Pharma A/S
F:22Z
|
DK |
Zealand Pharma A/S
Zealand Pharma is a Danish biotechnology company that discovers and develops peptide-based medicines. It does not sell consumer products; it builds drug candidates for diseases such as metabolic disorders and some rare conditions, then works to move them through testing and approval. Its core business is making medicines that can act like natural hormones and signaling molecules in the body, which is a useful approach when a disease is caused by a missing or weak biological signal. The company makes money mainly through partnerships with larger drug companies, along with payments tied to development progress and future sales of approved medicines. In practice, Zealand Pharma often creates the science and early drug assets, while a partner may help fund later-stage development, manufacturing, and commercialization. Its main customers are therefore pharmaceutical partners and, if a drug is approved, the patients and healthcare systems that use the medicine. What makes Zealand Pharma different is its role in the drug value chain. It is a specialist research company built around peptide drug design, which is a narrower and more technical field than traditional small-molecule drug discovery. That focus lets it concentrate on finding medicines that can mimic or replace natural body signals, while using partnerships to turn those discoveries into commercial products.
Zealand Pharma is a Danish biotechnology company that discovers and develops peptide-based medicines. It does not sell consumer products; it builds drug candidates for diseases such as metabolic disorders and some rare conditions, then works to move them through testing and approval. Its core business is making medicines that can act like natural hormones and signaling molecules in the body, which is a useful approach when a disease is caused by a missing or weak biological signal.
The company makes money mainly through partnerships with larger drug companies, along with payments tied to development progress and future sales of approved medicines. In practice, Zealand Pharma often creates the science and early drug assets, while a partner may help fund later-stage development, manufacturing, and commercialization. Its main customers are therefore pharmaceutical partners and, if a drug is approved, the patients and healthcare systems that use the medicine.
What makes Zealand Pharma different is its role in the drug value chain. It is a specialist research company built around peptide drug design, which is a narrower and more technical field than traditional small-molecule drug discovery. That focus lets it concentrate on finding medicines that can mimic or replace natural body signals, while using partnerships to turn those discoveries into commercial products.
Strategy: Zealand said it is on track with its Metabolic Frontier 2030 plan, using petrelintide, survodutide, a new Cambridge research hub, and AI partnerships to build a broader obesity and metabolic health franchise.
Petrelintide: The company highlighted positive Phase II ZUPREME-1 data, saying petrelintide delivered double-digit weight loss with a placebo-like safety and tolerability profile and is now expected to move into Phase III in the second half of 2026.
Survodutide: Boehringer Ingelheim’s Phase III SYNCHRONIZE-1 results were described as competitive, with up to 16.6% weight reduction at 76 weeks and meaningful metabolic benefits, supporting confidence in the partnered program.
Capital return: Zealand initiated a USD 200 million share buyback, saying its strong balance sheet and improved visibility on future cash flows allowed it to return capital without slowing R&D.
2026 outlook: Management left operating expense guidance unchanged, while raising collaboration revenue guidance to DKK 4.5 billion after confirmation of petrelintide Phase IIIa progression and related Roche payments.
